BioLineRx (BLRX) Tops Q2 EPS by 7c

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print
• BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)